Abstract

BackgroundPap screening, an effective method for cervical cancer prevention, is now supported by molecular human papillomavirus (HPV) testing. Recently commercialised preventive vaccines also provide new tools for the primary prevention of cervical cancer. To determine appropriate prevention strategies, the Health General Direction, Lombardy Region, funded a project that aims to characterize and monitor HPV infections and related cervical diseases in high-risk women.Methods/designVALHIDATE is a 5-year multicentre open prospective cohort study. It will recruit 7000 consenting women aged 13–65 years to provide information about the local biomolecular epidemiology of HPV infection and cervical diseases in high-risk women recruited from nine clinical centres and one faith-based organisation. The study will estimate the overall and type-specific prevalence of HPV infection and cervical abnormalities. It also aims to compare standard Pap screening with biomolecular screening, and to assist in the design of targeted regional prevention programs directed specifically at high-risk groups. Three groups of high-risk women: 1000 HIV-infected women (aged 26–65 years), 1000 recent migrant women (aged 26–65 years) and 3000 young women (aged 13–26 years) and 1 control group: 2000 women (aged 26–45 years) attending a spontaneous screening program, will be recruited. Sample sizes will be revised after the first year. Adult participants will undergo conventional cervical cytology, HPV DNA screening and genotyping. Paediatric participants will undergo HPV DNA testing and genotyping of urine samples. HPV DNA, cytological abnormalities and HPV types will be analysed according to demographic, epidemiological, behavioural, and clinical data collected in an electronic case report form. Overall and stratified prevalences will be estimated to analyse the associations between HPV infection and selected characteristics. Logistic regression models will be used to estimate crude and adjusted odds ratios. Cox proportional hazard models will be used to estimate hazard ratios over time and between groups.Discussion/main expected resultsThis study will provide substantial insight into HPV infections and related cervical diseases in high-risk groups and will help determine appropriate regional cervical cancer prevention strategies.

Highlights

  • Pap screening, an effective method for cervical cancer prevention, is supported by molecular human papillomavirus (HPV) testing

  • Cervical cancer screening with cervical cytology is a proven and effective secondary prevention strategy that can achieve a significant reduction in cervical cancer incidence in the industrialized world [1,2,3]

  • Developed secondary prevention strategies show promise for scaling up prevention services in both developing countries and the industrialized world. These strategies are based on human papillomavirus (HPV) testing for high-risk HPV types, which are a necessary intermediate step for the development of cervical cancer and its precursors

Read more

Summary

Background

Cervical cancer screening with cervical cytology is a proven and effective secondary prevention strategy that can achieve a significant reduction in cervical cancer incidence in the industrialized world [1,2,3]. Methods/design VALHIDATE (eVALuation and monitoring of HPV Infections and cervical relATEd Diseases in high-risk women) is a multicentre open cross-sectional and prospective cohort study conducted over a 5-year period (Dec. 2010–Dec. 2015) in the Lombardy Region. This study will provide substantial insight on HPV infections and related cervical diseases, which will enable us to define the risk of cervical cancer and its precursor lesions in high-risk women compared with the general population living in the Lombardy Region. This information will assist health care providers and policy makers to improve regional strategies and optimize cervical cancer prevention in high-risk groups. Study protocol Sacco Hospital Ethical Committee resolution n35 (3rd Feb 2010), Sacco Hosp General Direction Resolution n174/2010 (9 March 2010)

Runowicz CD
31. Ministero della salute – Direzione generale della prevenzione
40. Hall TA
Findings
42. Felsenstein J: Confidence limits on phylogenies
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call